Background and Future Considerations for Human Cord Blood Hematopoietic Cell Transplantation, Including Economic Concerns
Background and Future Considerations for Human Cord Blood Hematopoietic Cell Transplantation, Including Economic Concerns
复制标题
DOI：
10.1089/scd.2013.0382
复制
发表时间：
2013-12-01
影响因子：
4
通讯作者：
Farag, Sherif
中科院分区：
文献类型：
--
作者：
Broxmeyer, Hal E.;Farag, Sherif
自 1988 年以来，脐带血 (CB) 一直被用作造血干细胞 (HSC) 和造血细胞移植 (HCT) 祖细胞的来源，以治疗恶性和非恶性疾病患者。与 HCT 中也使用的其他 HSC 组织来源（例如骨髓和动员外周血）相比，CB 既有优点也有缺点。这篇简短的回顾重点关注一些历史信息，以及当前正在评估的提高 CB HCT 疗效的努力。同样重要的是CB的成本，以及使用CB的可行性和经济性，以及全球范围内为最大数量的患者新确认的改进。在这种情况下，不一定需要选定的细胞加工设施来离体扩展或改善CB移植物的功能活性的简单方法可能会引起人们的兴趣，其中一种可能性是使用二肽基肽酶4的口服活性抑制剂，单独或与其他新的和创新的方法相结合，以改善HSC植入和CB的体内再增殖能力。
Cord blood (CB) has been used since 1988 as a source of hematopoietic stem cells (HSCs) and progenitor cells for hematopoietic cell transplantation (HCT) to treat patients with malignant and nonmalignant disorders. CB has both advantages and disadvantages when compared with other tissue sources of HSCs such as bone marrow and mobilized peripheral blood, which are also being used in the setting of HCT. This short review focuses on some historical information, as well as current efforts that are being assessed to enhance the efficacy of CB HCT. Also of importance are the costs of CB, and the feasibility and economics of using such to be identified, and newly confirmed improvements worldwide for the greatest number of patients. In this context, simple methods that would not necessarily entail the need for selected cell-processing facilities to ex vivo expand or improve the CB graft's functional activity may be of interest, with one such possibility being the use of an orally active inhibitor of the enzyme dipeptidylpeptidase 4, alone or in combination with other new and innovative approaches for improving HSC engraftment and in vivo repopulating capability of CB.